What is Humanetics Corp?
Humanetics Corporation is a biotechnology firm dedicated to pioneering novel therapeutic strategies for solid tumor cancers. The company's primary focus is on enhancing patient outcomes during radiation therapy through its lead product, BIO 300. Beyond oncology, BIO 300 also shows promise in treating inflammatory lung diseases and serves as a critical medical countermeasure against radiation injuries, positioning Humanetics to address both civilian and military needs in the face of nuclear threats. Their work targets oncology patients, healthcare providers, and defense organizations, reflecting a dual mission of advancing cancer care and bolstering public safety.
How much funding has Humanetics Corp raised?
Humanetics Corp has raised a total of $125K across 1 funding round:
Debt
$125K
Debt (2021): $125K with participation from PPP
Key Investors in Humanetics Corp
PPP
Public-Private Partnership
What's next for Humanetics Corp?
With its large-scale, late-stage funding context, Humanetics Corp is poised for significant expansion and the acceleration of its product pipeline. The recent strategic investment suggests strong confidence from backers in the company's technology and market potential. This capital will likely be directed towards advancing clinical trials for BIO 300, potentially expanding its therapeutic applications, and scaling manufacturing capabilities to meet anticipated demand from both healthcare and defense sectors. The company's trajectory indicates a move towards commercialization and broader market penetration, solidifying its position as a key player in radiation oncology and radiation protection.
See full Humanetics Corp company page
